Net cash is $15.8M! 5 Mcap only £6m5 Jan 2024 10:29
28 September 2023
Trellus Health plc
("Trellus Health", the "Company" or the "Group")
Half-year Results
LONDON, U.K. AND NEW YORK, U.S. (28 September 2023). Trellus Health plc (AIM: TRLS), which is commercializing a scientifically validated and clinically proven personalized resilience-driven self-management solution for chronic health conditions at their intersection with mental health, announces its interim results for the period ended 30 June 2023.
Operational highlights (including post-period end)
· Launched a pilot program with a New York-based health insurance company with more than 1.8 million members to make Trellus Elevate™ IBD program available as a health plan benefit to certain members under its Medicaid managed care plan.
· Launched the Trellus Elevate™ program for IBS (irritable bowel syndrome).
· Expanded existing IBD agreement with Mount Sinai Health System to include the newly launched Trellus Elevate™ IBS for members of a large New York State labor union that offers health services and benefits to its members through Mount Sinai.
· Continued focus on B2B2C contract development, with ongoing engagement with existing DTC customers as described in detail below, and planned partnerships with provider organisations.
· Appointed Dr Daniel Mahony, Senior Independent Non-executive Director, as Non-executive Chairman, and Joy Bessenger as Chief Financial Officer.
Financial highlights
· Net cash of $15.81m at 30 June 2023